Gyre Therapeutics (GYRE) Expected to Announce Earnings on Thursday

Key Points

• Gyre Therapeutics will report Q1 2026 results before the market opens on Thursday, May 7, with analysts projecting EPS of ($0.0733) and revenue of $31.61 million; a conference call is scheduled for May 8 at 9:30 AM ET.
• The company recently missed EPS estimates (reported $0.04 vs. $0.08 expected) while posting $37.2 million in revenue, and its stock trades around $7.35 with a $712.9M market cap; analysts hold a consensus "Hold" rating and a $17 target after several downgrades.
• Gyre is a clinical-stage biotech focused on lipid-targeted small-molecule therapies across NASH, Alzheimer’s and autoimmune programs, with notable recent institutional buying that leaves about 24% of shares held by institutions.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) is expected to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Gyre Therapeutics to post earnings of ($0.0733) per share and revenue of $31.6070 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 9:30 AM ET.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%. On average, analysts expect Gyre Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Gyre Therapeutics Price Performance

NASDAQ GYRE opened at $7.35 on Thursday. The company has a market cap of $712.91 million, a P/E ratio of 735.74 and a beta of 2.10. The stock has a 50-day moving average of $7.63 and a two-hundred day moving average of $7.72. Gyre Therapeutics has a 1-year low of $6.57 and a 1-year high of $11.78.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Zacks Research downgraded Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Monday, March 16th. Wall Street Zen downgraded Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $17.00.

Hedge Funds Weigh In On Gyre Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its position in shares of Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company's stock worth $131,000 after buying an additional 5,135 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 37.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company's stock worth $1,194,000 after purchasing an additional 45,772 shares during the last quarter. State Street Corp lifted its stake in Gyre Therapeutics by 10.7% during the fourth quarter. State Street Corp now owns 202,225 shares of the company's stock worth $1,428,000 after purchasing an additional 19,472 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company's stock worth $91,000 after purchasing an additional 7,361 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Gyre Therapeutics during the fourth quarter worth approximately $77,000. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.